Streptomyces: boost chassis strains for production of invaluable natural products Authors: Simin Chen, Siqi Ling, Jinpin Li, Zhiyan Liu, Lixin Zhang, Jingyu Zhang Published: 2026 ABSTRACT AbstractStreptomyces species continue to occupy a pivotal role in natural product biosynthesis, owing to their unparalleled metabolic diversity and genetic adaptability. This review focuses on cutting-edge advances documented from 2020 to 2025 (encompassing approximately 150 cases), with particular emphasis on innovations in canonical/non-canonical Streptomyces chassis engineering. We synthesize key developments across genome streamlining, mitigation of endogenous interference, redistribution of precursors and cofactors, regulatory circuit reprogramming, optimization of phylogenetic host-cluster compatibility, and enhancement of fermentation robustness. These strategies collectively transform Streptomyces into versatile, application-specific production platforms. A standout innovation highlighted herein is the 5M strategy (Mechanism–Model–Manipulate–Measure–Manufacture), which reframes chassis engineering as an iterative, systems-level process inspired by engineering principles. This framework fosters precise manipulation and strain-bioreactor synergy, based on a deep comprehension of metabolic mechanisms and bioreactor compatibility dynamics, thereby facilitating scalable manufacturing of high-value compounds. By providing a structured roadmap, this perspective equips researchers with actionable insights for advancing next-generation Streptomyces chassis in synthetic biology and industrial biotechnology. Furthermore, we explore emerging technological breakthroughs, such as AI-driven design tools, multiplexed genome editing technologies, and hybrid chemical-enzymatic integration strategies, that are poised to accelerate the evolution toward intelligent, modular chassis architectures. Ultimately, this review offers a practical resource for advancing Streptomyces applications in natural product discovery, functional characterization, and yield enhancement, supporting incremental improvements in biotechnological applications.Keywords: Streptomyces, Natural products, Heterologous expression, Biosynthetic gene clusters, Synthetic biology, Chassis engineering, Secondary metabolites Introduction Streptomyces, which provided the foundation in the field of natural products (NPs) research, is widely recognized for its excellent biosynthetic ability. The genus has been responsible for the production of nearly 100,000 bioactive NPs [[1], [2], [3]], contributing to approximately two-thirds of microbial antibiotics and accounting for 70–80% of the bioactive entities used in the pharmaceutical arsenal and contemporary medicine [4]. These NPs are synthesized by multiple tailoring enzymes encoded within BGCs, which are abundantly present in the genomes of Streptomyces species [5]. However, the majority of these BGCs remain silent or cryptic under standard laboratory conditions, concealing a vast reservoir of untapped NPs chemistry [6]. Attempts to decipher these cryptic BGCs are hindered by the complexity and insufficient characterization of the genetic regulatory networks controlling their expression, as well as the slow growth rates and limited genetic tractability of many wild-type Streptomyces strains [7]. To overcome this significant impediment in drug development and to successfully unearth the invaluable trove of multiple, potentially bioactive molecules, a robust discovery and production platform is required that supplies NPs and their derivatives in sufficient quantities [8]. Heterologous expression has emerged as a suitable approach for effective production of valuable bioactive NPs by transferring target BGCs into genetically tractable, fast-growing host strains [9]. This strategy promotes the identification and production of previously uncharacterized NPs, while emphasizing Streptomyces as a critical source of novel bioactive compounds and underscoring its vital contribution to the advancement of NP discovery. Compared to other versatile host systems such as Escherichia coli, Bacillus species, or yeast, Streptomyces species possess several notable features that make them suitable chassis hosts: (1) the abundant availability of essential natural components, such as precursors and cofactors, which are indispensable for the biosynthesis of NPs; (2) a sophisticated post-modification system, enabling structural tailoring of complicated NPs; (3) an inherent antibiotic resistance and tolerance, facilitating the synthesis of bioactive compounds; (4) an advanced protein folding system, crucial for the proper assembly and functionality of multi-enzyme complexes; and (5) a more suitable cellular environment, including optimal pH and redox potential, that supports the production of intricate molecules. These distinct advantages render Streptomyces a specialized host for the production of NPs. In recent years, Streptomyces has evolved from a traditional antibiotic-producing organism into a rationally engineered chassis for NP discovery, biosynthetic pathway characterization, and yield improvement. A clear trend emerging from recent studies is the shift from empirical utilization of native strains toward design-driven chassis engineering [10]. Nevertheless, the performance of Streptomyces chassis remains constrained by several challenges, including limited genetic accessibility, endogenous metabolic interference, insufficient precursor and cofactor supply, regulatory incompatibility between host and heterologous BGCs, and insufficient robustness during large-scale fermentation. These limitations have driven the development of systematic engineering strategies aimed at improving chassis performance at multiple levels. Accordingly, this review focuses on recent advances in Streptomyces chassis development and engineering, with particular emphasis on progress reported from 2020 to 2025. We first revisit advances in the taxonomy and phylogenomics of the genus Streptomyces, highlighting how evolutionary relationships inform rational chassis selection and diversification across phylogenetic lineages. We then summarize representative Streptomyces chassis strains and discuss key engineering strategies, including enhancement of genetic accessibility, elimination of endogenous biosynthetic interference, optimization of precursor and cofactor supply, regulatory network reprogramming, improvement of process robustness, and the development of non-canonical chassis guided by phylogenetic compatibility. Building on these foundations, we further examine how engineered Streptomyces chassis have been applied to NP discovery, BGC functional characterization, and production improvement. Finally, we highlight the 5M-oriented framework (Mechanism-Model-Manipulate-Measure-Manufacture) as an emerging systems-level strategy for guiding future chassis design and for bridging fundamental biosynthetic understanding with industrial translation. Taxonomy of the genus Streptomyces The genus Streptomyces, which belongs to the phylum Actinobacteria, are Gram-positive bacteria with a filamentous form and are widely distributed in soil environments [11]. Renowned for their complex life cycle and soil-dwelling nature, Streptomyces species exhibit a mycelial growth pattern similar to fungi, forming aerial hyphae and spore chains [12]. The genus Streptomyces has long been a subject of intense taxonomic study due to its remarkable diversity and importance in NP biosynthesis [13]. Early classification relied heavily on phenotypic characteristics, such as morphology, biochemical profiles, and the ability to produce specific metabolites [14]. However, this approach proved to be challenging due to significant variability in phenotypic traits, leading to inconsistent and imprecise classifications. In the late 1960s and 1970s, the International Streptomyces Project (ISP) introduced numerical taxonomy and chemical classification methods, aiming to resolve these inconsistencies by analyzing a broader array of characteristics, such as whole-cell sugar profiles and protein patterns [15,16]. Despite advances, the inherent complexity of Streptomyces led to repeated reclassification, with several strains being identified multiple times under different species names [17]. The emergence of molecular biological techniques has revolutionized the taxonomic classification system of Streptomyces, representing a fundamental transformation in microbial systematics. In the 1980s, molecular techniques such as 16S rRNA gene sequencing were introduced, which provided a more reliable means of inferring evolutionary relationships [18]. By utilizing key housekeeping genes, multi-locus sequence analysis (MLSA) enhanced phylogenetic resolution, resulting in a classification system with improved accuracy and reproducibility [19]. This shift toward molecular methods contributed to clarifying the genetic boundaries between Streptomyces species and related genera, facilitating the identification of new taxa and refinement of the family structure [20]. Recent studies have continued to evolve the taxonomy of Streptomyces, with efforts to separate certain species into new genera based on genomic data. For example, Komaki reclassified S. anthocyanicus and S. tricolor as synonyms of S. violaceoruber, which was revealed by MLSA after resequencing housekeeping genes and conducting phenotypic comparison [21]. As of February 17, 2025, the genus Streptomyces comprises 1360 species listed in the List of Prokaryotic names with Standing in Nomenclature (LPSN) [22], accessible at https://lpsn.dsmz.de/family/streptomycetaceae. These advances underscore the dynamic nature of Streptomyces taxonomy, driven by both the discovery of novel species and the increasing availability of genomic data. Overall, the classification of Streptomyces has evolved from a primarily phenotypic approach to a more robust molecular framework [23]. Modern techniques, including 16S rRNA analysis, MLSA, and genomic sequencing, have significantly improved our understanding of the evolutionary relationships within this genus [24]. Importantly, phylogenetic relationships often correlate with conserved regulatory architectures, metabolic capacities, and biosynthetic repertoires, all of which influence a strain's suitability as a preferred heterologous host. Genome-resolved taxonomy enables the identification of phylogenetically distinct or underexplored clades that may serve as alternative chassis with reduced endogenous secondary metabolic background [25], thereby improving metabolite detectability and downstream purification. Moreover, phylogenetic proximity between a chassis and the native producer can inform predictions of BGC compatibility, including promoter recognition, precursor availability, and pathway regulation [8,26]. Importantly, the study by Sean Qiu En Lee et al. [25] has moved beyond retrospective analyses and instead adopted a rational, phylogeny-guided strategy by selecting and designating S. sungeiensis SD3 as a new chassis. Notably, leveraging a chassis with closer evolutionary proximity to the native producer can increase the probability of productive NP expression. As such, taxonomy-informed phylogenomic analysis provides a rational starting point for host discovery, comparative chassis evaluation, and subsequent engineering strategies, forming a conceptual bridge between Streptomyces systematics and their applications in engineered biomanufacturing chassis discussed in the following sections. Streptomyces: an ideal platform for NP production with complex architecture and significant bioactivity The genus Streptomyces has historically been one of the most prolific sources of clinically and industrially important NPs (Fig. 1), accounting for nearly two-thirds of known antibiotics [11]. Classical discoveries include polyketides (PKs) such as avermectin [27], daunorubicin [28], doxorubicin [29], amphotericin B [30], tacrolimus [31], and tetracycline [32]; nonribosomal peptides (NRPs) such as actinomycin D [33] and daptomycin [34]; hybrid PKS-NRPS products such as pristinamycin [35] and bleomycin [36]; aminoglycosides such as streptomycin [37], neomycin [38], paromomycin [39], and kanamycin [40]. These metabolites span antibacterial, antifungal, antiviral, antiparasitic, anticancer, and immunomodulatory activities, underscoring the exceptional biosynthetic versatility of the genus. Although the pace of antibiotic discovery slowed in the late 20th century due to rediscovery and technical limitations, advances in genome sequencing and genome mining have revealed that Streptomyces genomes harbor far more BGCs than previously recognized [41], many of which remain cryptic or silent. This immense and still underexploited biosynthetic capacity provides the fundamental rationale for developing Streptomyces as an engineered chassis for efficient BGC activation, biosynthesis characterization, and scalable production. Some bioactive NPs derived from Streptomyces. Streptomyces species serve as a robust heterologous expression platform Building upon this unparalleled biosynthetic potential, Streptomyces have become pivotal heterologous expression platforms for NP discovery and development. Their genomes encode a vast diversity of BGCs, yet many remain silent or poorly expressed under standard laboratory conditions, limiting systematic exploitation of their metabolic potential [42,43]. Advances in genomics, genome mining, and synthetic biology have expanded the functional understanding of Streptomyces and established these organisms as competitive hosts alongside conventional microbial platforms such as E. coli and Saccharomyces cerevisiae [44,45]. Advanced genome editing toolkits available for several Streptomyces host strains enable precise gene deletion and targeted integration, facilitating the rational rewiring of NP biosynthetic pathways to enable discovery and improve titers. In parallel, Streptomyces provide strong metabolic support for NPs production, including sufficient precursor supply and versatile tailoring capacity. They can carry out key post-biosynthetic modifications such as phosphorylation, acetylation, prenylation, and glycosylation, which often contribute to the structural diversity and bioactivity of NPs [46]. These features have enabled reconstruction of structurally complex secondary metabolite pathways that are often difficult to implement in non-actinomycete hosts [47]. Among available species, S. coelicolor serves as the classical genetic model. Its 8.7 Mb genome contains more than 40 annotated BGCs responsible for metabolites such as actinorhodin, prodigiosin, and calcium-dependent antibiotics [41]. The depth of genetic and regulatory characterization has made S. coelicolor a widely adopted platform for heterologous expression of BGCs from both Streptomyces and phylogenetically distant actinobacteria [8,48]. S. lividans, a closely related species, is frequently selected for its broad compatibility with foreign pathways and efficient protein secretion capacity. Derivatives such as TK24 and K4-114 have supported expression of diverse biosynthetic systems, including clinically relevant pathways such as daptomycin biosynthesis [34,[49], [50], [51]]. Its balanced regulatory background and fermentation performance make it suitable for both pathway reconstruction and metabolite overproduction. S. albus has emerged as a preferred chassis species when reduced endogenous interference and high genetic accessibility are prioritized. Among its derivatives, S. albus J1074 is the most widely used strain for heterologous expression due to its streamlined genome and efficient DNA transfer systems [[52], [53], [54], [55], [56]]. The species provides a relatively clean background metabolite profile, facilitating detection and characterization of heterologous products [57], and has supported expression of multiple PKS and hybrid pathways in discovery-oriented studies [45,[58], [59], [60], [61]]. S. avermitilis, originally developed for industrial avermectin production, contains numerous cryptic BGCs beyond its primary products [62]. Genome-modified derivatives have been repurposed as flexible hosts capable of accommodating diverse exogenous clusters [63]. These strains have supported pathway reconstruction across multiple biosynthetic classes and illustrate how host metabolic context influences final product profiles [[64], [65], [66], [67], [68]]. S. venezuelae has gained attention as a rapid-iteration chassis due to its fast growth cycle and well-annotated genome [69]. Engineered derivatives have enabled expression of diverse PKS and NRPS pathways [[70], [71], [72], [73], [74]], while its glycosylation machinery supports structural diversification of macrolide compounds [[75], [76], [77]]. These features make S. venezuelae suitable for iterative pathway testing and synthetic regulation studies. Collectively, these classical chassis species represent distinct but complementary host types within the Streptomyces genus. However, persistent bottlenecks, including transcriptionally silent clusters, host-cluster incompatibility, endogenous metabolic competition, precursor imbalance, and scale-up constraints, have highlighted the limitations of relying solely on unmodified model hosts. This has driven the transition toward a more diversified and design-oriented chassis spectrum, in which host selection and engineering are increasingly aligned with pathway characteristics and application objectives. To translate these intrinsic advantages into practical heterologous production platforms, extensive strain engineering efforts have been undertaken to streamline genomes, remove competing pathways, and optimize regulatory backgrounds in these classical chassis species. Representative engineering strategies and their functional outcomes are summarized in Table 1. These engineered derivatives illustrate the transition from classical model strains to functionally optimized chassis, highlighting how targeted genome modification enhances heterologous production capacity across diverse biosynthetic classes. Table 1Engineering of canonical chassises and corresponding outcomes.Table 1Heterologous hostEngineered strain constructionOutcomeReferenceS. coelicolor●Plasmid-free mutant constructed; actinorhodin BGC deleted●6-deoxyerythronolide B yield increased to 40 mg/L[148]●Genome-minimized strains (M1152, M1154) with ΔAct/Red/CDA/Cpk and rpsL/rpoB mutations●Chloramphenicol yield increased 20 to 40-fold[48,149]●Type III PKS-deficient S. coelicolor M1317 (Δgcs/srsA/rppA)●Germicidin and flaviolin production increased[44]●Δ10 PKS/NRPS BGCs and 900 kb telomeric deletion●Actinorhodin yield increased 4-fold[150]●ΔwblA, ΔorrA, ΔgntR via CRISPR/Cas9●Aborycin yield increased to 56.3 mg/L[151]●New plasmid-based system utilized●Oviedomycin yield increased to 670 mg/L[144]S. lividans●ΔAct/Red clusters●Improved background for heterologous NP expression[50]●Promoter mining with σ^hrdB regulation●Indigoidine yield increased to 14.3 g/L (shake flask) and 46.27 g/L (4 L fermenter)[152]S. albus●Δ15 native BGCs●Facilitates detection of heterologous products[57]●Δantimycin, Δcandicidin, Δalbaflavenone, Δsurugamide, Δfredericamycin●cleaner chromatographic background[136]●Added attB sites●increased production of didesmethylmensacarcin, griseorhodin A, aloesaponarin II, didemethoxyaranciamycinone, and cinnamycin[153]S. avermitilis●Δ non-essential BGCs and metabolic elements●Host for nearly 20 exogenous BGCs[63]●Δ endogenous secondary metabolites (including avermectins)●Discover 12-ketomethymycin N-oxide[65]S. venezuelae●Δ desosamine BGC and kanamycin resistance marker●Enhanced production of gentamicin and kanamycin[71,73]●Δ entire pikromycin PKS cluster●Facilitates diverse biosynthetic system expression[70]●Δ pikromycin PKS and desosamine clusters●Produce tylosin and doxorubicin[75] Engineering of canonical chassises and corresponding outcomes. ●Plasmid-free mutant constructed; actinorhodin BGC deleted Plasmid-free mutant constructed; actinorhodin BGC deleted ●6-deoxyerythronolide B yield increased to 40 mg/L 6-deoxyerythronolide B yield increased to 40 mg/L ●Genome-minimized strains (M1152, M1154) with ΔAct/Red/CDA/Cpk and rpsL/rpoB mutations Genome-minimized strains (M1152, M1154) with ΔAct/Red/CDA/Cpk and rpsL/rpoB mutations ●Chloramphenicol yield increased 20 to 40-fold Chloramphenicol yield increased 20 to 40-fold ●Type III PKS-deficient S. coelicolor M1317 (Δgcs/srsA/rppA) Type III PKS-deficient S. coelicolor M1317 (Δgcs/srsA/rppA) ●Germicidin and flaviolin production increased Germicidin and flaviolin production increased ●Δ10 PKS/NRPS BGCs and 900 kb telomeric deletion Δ10 PKS/NRPS BGCs and 900 kb telomeric deletion ●Actinorhodin yield increased 4-fold Actinorhodin yield increased 4-fold ●ΔwblA, ΔorrA, ΔgntR via CRISPR/Cas9 ΔwblA, ΔorrA, ΔgntR via CRISPR/Cas9 ●Aborycin yield increased to 56.3 mg/L Aborycin yield increased to 56.3 mg/L ●New plasmid-based system utilized New plasmid-based system utilized ●Oviedomycin yield increased to 670 mg/L Oviedomycin yield increased to 670 mg/L ●ΔAct/Red clusters ΔAct/Red clusters ●Improved background for heterologous NP expression Improved background for heterologous NP expression ●Promoter mining with σ^hrdB regulation Promoter mining with σ^hrdB regulation ●Indigoidine yield increased to 14.3 g/L (shake flask) and 46.27 g/L (4 L fermenter) Indigoidine yield increased to 14.3 g/L (shake flask) and 46.27 g/L (4 L fermenter) ●Δ15 native BGCs Δ15 native BGCs ●Facilitates detection of heterologous products Facilitates detection of heterologous products ●Δantimycin, Δcandicidin, Δalbaflavenone, Δsurugamide, Δfredericamycin Δantimycin, Δcandicidin, Δalbaflavenone, Δsurugamide, Δfredericamycin ●cleaner chromatographic background cleaner chromatographic background ●Added attB sites Added attB sites ●increased production of didesmethylmensacarcin, griseorhodin A, aloesaponarin II, didemethoxyaranciamycinone, and cinnamycin increased production of didesmethylmensacarcin, griseorhodin A, aloesaponarin II, didemethoxyaranciamycinone, and cinnamycin ●Δ non-essential BGCs and metabolic elements Δ non-essential BGCs and metabolic elements ●Host for nearly 20 exogenous BGCs Host for nearly 20 exogenous BGCs ●Δ endogenous secondary metabolites (including avermectins) Δ endogenous secondary metabolites (including avermectins) ●Discover 12-ketomethymycin N-oxide Discover 12-ketomethymycin N-oxide ●Δ desosamine BGC and kanamycin resistance marker Δ desosamine BGC and kanamycin resistance marker ●Enhanced production of gentamicin and kanamycin Enhanced production of gentamicin and kanamycin ●Δ entire pikromycin PKS cluster Δ entire pikromycin PKS cluster ●Facilitates diverse biosynthetic system expression Facilitates diverse biosynthetic system expression ●Δ pikromycin PKS and desosamine clusters Δ pikromycin PKS and desosamine clusters ●Produce tylosin and doxorubicin Produce tylosin and doxorubicin Chassis usage landscape and pathway preference (2020–2025) To systematically evaluate recent chassis selection patterns in Streptomyces heterologous expression studies, we conducted a literature survey of primary research articles indexed in the Web of Science database from 2020 to 2025 using combinations of the keywords “Streptomyces” and “heterologous expression”. After excluding review articles and studies lacking explicit chassis identification, publications (143 cases) were manually curated and categorized according to chassis species, biosynthetic pathway type (PKS, NRPS, PKS-NRPS hybrid, RiPP, and terpene), and primary research objective (comprising 64 discovery-oriented cases, 79 functional characterization-oriented cases, and 39 yield improvement-oriented cases). Each chassis-pathway pair was counted independently when multiple systems were evaluated in a single study. Percentages shown in Fig. 2 were normalized within each objective category to reflect relative distribution rather than absolute publication numbers. Usage density of common chassis strains and their corresponding products across three research orientations (2020–2025). Values are presented as percentages (%), reflecting the relative usage density of each chassis-product combination within a given research orientation. Color intensity corresponds to relative frequency, with darker shades indicating higher usage density. Hybrid includes both PKS-NRPS hybrid and PKS-terpene hybrid biosynthetic products. (A) Discovery-oriented (%). Relative usage density of chassis strains in new NP discovery and cryptic BGC activation; (B) Functional characterization-oriented (%). Relative usage density of chassis strains in heterologous expression and biosynthetic pathway characterization; (C) Yield-oriented (%). Relative usage density of chassis strains in studies focused on titer improvement and production optimization. In discovery-oriented studies (Fig. 2A), chassis usage exhibits a relatively dispersed yet pathway-sensitive distribution pattern. For PKS pathways, S. avermitilis shows the highest proportional representation (60%), followed by S. coelicolor (36.7%) and S. albus (33.3%), respectively, likely reflecting its evolutionarily expanded and diversified PKS domain architecture—particularly variation in AT, DH, and KR domains alongside conserved KS cores—which may enhance compatibility with heterologous PKS modules [78]. In NRPS-based discovery, S. lividans displays the strongest proportional contribution (50%), underscoring its prominent role in peptide-cluster activation and screening. Hybrid PKS-NRPS systems are enriched in S. avermitilis (50%), suggesting that the chassis may be inherently more compatible with the discovery of complex modular assembly-line pathways. RiPP discovery is largely concentrated in S. albus (50%), while terpene discovery remains restricted to S. albus and S. coelicolor (50% each). Transitioning to functional characterization and mechanistic validation (Fig. 2B), the distribution shifts toward genetically tractable and experimentally established model hosts. S. albus demonstrates strong representation across PKS (44.4%), Hybrid (50%), and RiPP (50%) systems, highlighting its versatility for pathway confirmation and gene-function analysis. S. coelicolor exhibits particularly high enrichment in Hybrid pathways (88.9%) along with consistent involvement in PKS and NRPS systems, reinforcing its central role in dissecting modular biosynthetic logic [48]. Meanwhile, S. lividans shows complete proportional representation in terpene systems (100%) and strong enrichment in hybrid pathways (66.7%, including PKS-NRPS and PKS-terpene hybrids), indicating its suitability for enzyme-level validation and cluster reconstruction. Compared with discovery-oriented work, functional studies display a more balanced distribution across pathway classes but remain anchored to hosts with predictable genetics and well-established molecular toolkits. In contrast to discovery- and functional-oriented investigations, yield-improvement studies (Fig. 2C) display a comparatively lower overall proportional representation across most chassis-pathway combinations. This distribution is consistent with the sequential logic of NP research, in which pathway activation and mechanistic elucidation typically precede systematic production engineering. Consequently, only a subset of biosynthetic systems progresses to the stage of yield optimization. Among these, production-oriented efforts are predominantly focused on PKS and NRPS pathways. Representative PKS examples include fidaxomicin [79], tetracenomycin X [80], spinosad [81], and nybomycin [82], while NRPS-centered yield enhancement targets bioactive compounds such as daptomycin [83], thaxtomin A [84], and staurosporine [85]. Notably, Fig. 2C indicates that S. avermitilis and S. venezuelae show relatively stronger representation in yield-oriented studies, suggesting their suitability for high-level production engineering. S. avermitilis displays complete proportional representation in terpene systems (100%) and substantial representation in NRPS pathways (50%), consistent with its established role as an industrial producer of avermectin and related compounds [86]. Engineered derivatives such as the SUKA strains further demonstrate enhanced genome streamlining and production capacity [87]. Similarly, S. venezuelae exhibits complete proportional representation in NRPS systems (100%), which may be attributed to its rapid growth, genetic tractability, reduced mycelial aggregation, and ability to sporulate in liquid culture, features that facilitate scalable engineering and production optimization [88,89]. Rather than relying on a single universal host, recent studies demonstrate context-dependent selection aligned with pathway architecture, experimental purpose, and translational stage. Discovery efforts prioritize activation compatibility and modular tolerance, functional studies emphasize genetic tractability and regulatory predictability, and yield-oriented engineering selectively advances biosynthetic systems with established bioactivity toward production refinement. This stratified usage pattern reflects a transition from opportunistic host choice toward increasingly intentional and performance-informed chassis selection. Such an evolution naturally motivates the next phase of development—moving beyond empirical host utilization toward systematic, design-driven optimization of Streptomyces chassis to enhance compatibility, regulatory coherence, and biosynthetic efficiency. Design-driven engineering of Streptomyces chassis The differentiated chassis deployment patterns described in the introduction of Section 4 are not incidental, but rather the outcome of systematic, design-driven engineering efforts. Modern Streptomyces chassis are no longer selected solely based on historical precedent; instead, they are deliberately reconfigured to address specific genetic, metabolic, and process-level constraints that limit heterologous biosynthesis [42,43]. These engineering strategies converge on several core objectives: improving genetic accessibility, reducing endogenous interference, reinforcing metabolic flux, reprogramming regulatory networks, enhancing industrial robustness, and optimizing phylogenetic host-cluster compatibility [10]. Enhancing genetic tractability Improving genetic tractability is the foundational step in Streptomyces chassis engineering, as precise genome manipulation underlies pathway refactoring, regulatory rewiring, and host optimization [10]. From 2020 to 2025, major advances have focused on expanding genome editing toolkits, improving editing efficiency in high-GC actinomycetes, and integrating synthetic biology frameworks for systematic strain development. CRISPR/Cas-based systems have become the central platform for genome editing and transcriptional control in Streptomyces, dramatically reducing the time required for strain construction and enabling multiplex modification of BGCs [10,[90], [91], [92]]. Beyond SpCas9-derived systems, alternative nucleases have been introduced to address Protospacer Adjacent Motif (PAM) constraints and editing inefficiencies in GC-rich genomes. Notably, three CRISPR-FnCas12a variants were developed for efficient multiplex editing [93]. CRISPR-FnCas12a1 improves performance in strains where Cas9 activity is suboptimal; CRISPR-FnCas12a2 enables deletion of large genomic fragments (21.4-128 kb); and CRISPR-FnCas12a3, incorporating an engineered EP16 mutant with broadened PAM recognition, supports precise site mutations and insertions in high-GC contexts. These systems expand editable genomic space and enhance flexibility in chassis design. Nevertheless, only a limited number of CRISPR types have been validated in Streptomyces, and species-specific optimization remains necessary due to interspecies variability [90]. In parallel with nuclease diversification, transcriptional regulation tools have also matured. CRISPR interference (CRISPRi) based on catalytically inactive dCas9 enables programmable gene repression and regulatory network interrogation, facilitating functional screening of smBGCs and regulatory elements [10]. Such programmable regulation supports rapid evaluation of gene function without permanent genomic modification, increasing experimental throughput. Efficient manipulation of large biosynthetic gene clusters remains a distinctive technical challenge in Streptomyces. To address this, advanced DNA capture and assembly technologies, including BAC-based transformation [94], RecET direct cloning [95], and transformation-associated recombination (TAR) [96], have been adapted for high-GC actinomycetes [92]. These platforms enable cloning, refactoring, and modular reconstruction of multi-kilobase smBGCs, supporting more predictable heterologous expression. Integration of DNA synthesis and standardized assembly strategies further promotes modular pathway engineering and reduces dependence on native regulatory architectures [10]. Beyond individual tools, the conceptual framework for chassis engineering has shifted toward systematic and iterative design. Integration of multi-omics datasets from genomics, transcriptomics, proteomics, and metabolomic provide system-level insight into regulatory and metabolic constraints, guiding rational modification strategies [97]. These datasets increasingly feed into Design-Build-Test-Learn (DBTL) cycles [98], enabling structured evaluation of genetic interventions and accelerating strain optimization [99]. Emerging efforts toward automation of cloning, smBGC refactoring, and expression screening aim to further scale up exploration of uncharacterized clusters [92]. Collectively, advances in CRISPR-based editing, nuclease diversification, programmable transcriptional regulation, large-DNA manipulation platforms, and systems-guided design have substantially enhanced the genetic tractability of Streptomyces. Although tool portability across diverse species remains imperfect [100], the expanded genetic toolkit now supports increasingly precise, multiplex, and high-throughput chassis engineering, laying the technical foundation for the metabolic and regulatory optimization strategies discussed in subsequent sections. Minimizing endogenous metabolic interference Following the establishment of efficient genome editing tools, a central objective in Streptomyces chassis engineering has been the reduction of endogenous metabolic interference. Native secondary metabolite pathways compete for precursors, ATP, and reducing power, generate complex metabolite backgrounds, and can obscure detection of heterologous products [101]. Genome streamlining, particularly deletion of endogenous BGCs, has therefore become a widely adopted strategy to create metabolically cleaner and more predictable hosts [102,103]. Most genome reduction efforts follow a top-down strategy, in which dispensable genomic regions, including secondary metabolite clusters and insertion sequences, are systematically removed from the native chromosome. This approach reduces metabolic burden and simplifies regulatory complexity while improving genetic stability [102,103]. In practice, deletion targets are selected based on transcriptomic activity, predicted dispensability, and potential competition with desired pathways. A representative example is S. tsukubaensis L19, where deletion of core PKS genes in transcriptionally active BGCs generated strain L19-2, resulting in a cleaner metabolic background and a 21.4% increase in FK506 production [104]. Such cases illustrate how removal of competing pathways can directly enhance flux toward target metabolites. Several genome-reduced chassis systems have become reference platforms in the field. In S. coelicolor, strains M1152 and M1154 were constructed through deletion of four major endogenous clusters (act, red, cpk, and cda), combined with beneficial mutations in rpoB (M1152) and rpoB/rpsL (M1154) [105]. These modifications improved heterologous gene expression and secondary metabolite production, partly attributed to altered RNA polymerase affinity and enhanced protein synthesis. In S. albus, the Del14 strain (harboring deletions of 15 endogenous BGCs) provides a clean metabolic background that facilitates activation of cryptic clusters and improves production of polyketides, nucleosides, and other structurally diverse metabolites [82]. Large-scale genome reduction has also been implemented in S. avermitilis through the SUKA series, involving deletions of up to 1.4 Mb and removal of multiple BGCs. These strains retained normal growth and genomic stability while achieving up to 2.7-fold higher production of heterologous products such as streptomycin and cephamycin C [102]. Similarly, S. lividans ΔYA11, constructed by deleting 11 gene clusters (228.5 kb) and introducing additional attB sites, exhibited a fourfold increase in lanthipeptide deoxycinnamycin production and improved growth characteristics [103]. Collectively, these systems demonstrate that substantial genome reduction can be achieved without compromising viability, while improving chassis suitability for heterologous expression. Comparative analyses further indicate that genome-reduced strains exhibit pathway-dependent specialization. For example, S. lividans ΔYA11 performed better for deoxycinnamycin production [9], whereas S. albus Del14 showed superior nybomycin output [82]. Moreover, such findings may also provide clues for the expression of other NPs. Nonetheless, removal of endogenous BGCs consistently enhances heterologous production capacity and facilitates detection of previously silent or low-abundance metabolites [6]. The rapid construction of genome-reduced chassis has been made possible by advances in CRISPR/Cas and other site-specific recombination systems, which enable precise, multiplex, and large-fragment deletions [106]. These tools allow simultaneous modification of multiple genomic loci, accelerating the generation of metabolically simplified strains tailored to specific biotechnological objectives [106]. Despite these advances, the development of a truly universal Streptomyces chassis remains challenging. Host-specific regulatory contexts and metabolic configurations influence BGC expression efficiency, and certain pathways perform optimally only in particular genetic backgrounds [9,99]. As a result, the concept of a specialized chassis optimized for distinct classes of secondary metabolites has gained increasing support [99]. Ongoing efforts focus on refining deletion strategies, improving genome stability, and systematically evaluating chassis-pathway compatibility to enhance industrial robustness and discovery efficiency [106]. A complementary genome-reduction strategy was implemented in the fast-growing rhizosphere-derived strain Streptomyces sp. A-14 [107], where CRISPR/Cas-mediated stepwise refinement reduced the genome from 7.47 Mb to 6.13 Mb through deletion of nonessential regions and endogenous BGCs while largely preserving growth. The streamlined strain exhibited a cleaner metabolic background and supported efficient heterologous expression of actinorhodin and polycyclic tetramate macrolactams, indicating that rational genome minimization can enhance chassis suitability for heterologous production. In summary, genome streamlining and endogenous BGC deletion have emerged as core strategies for minimizing metabolic interference in Streptomyces chassis. Representative systems such as M1152/M1154, Del14 and SUKA illustrate how targeted genome reduction can generate cleaner, more stable, and functionally specialized hosts. While universal solutions remain elusive, the systematic development of minimized and pathway-adapted chassis libraries represents a pragmatic direction for advancing heterologous expression and NPs discovery. Optimization of precursor and cofactor supply Strengthening metabolic flux toward target NPs through precursor and cofactor optimization has become a central strategy in Streptomyces chassis engineering. While genome streamlining reduces endogenous interference, efficient heterologous production further depends on directing carbon flux, redox balance, and energy supply toward introduced BGCs. Recent studies demonstrate that multi-level metabolic rewiring, including precursor amplification, competing pathway deletion, redox engineering, and ATP/NADPH optimization, significantly enhances production titers and pathway stability [108]. Precursor pathway amplification is a primary approach to reinforce metabolic flux toward PKS, NRPS, and other secondary metabolites. In engineered S. albus strains, stepwise metabolic engineering combining promoter replacement, activator overexpression, transporter enhancement, and pathway balancing led to a 15-fold increase in fidaxomicin production compared to the native producer [109]. This study exemplifies how reinforcing precursor supply and pathway expression synergistically elevates yield. Similarly, identification of a strong constitutive promoter (stnYp) enabled 1.4- to 11.6-fold higher production of diverse metabolites in multiple Streptomyces hosts, and improved tylosin A production to 10.30 g/L, demonstrating that transcriptional strengthening can effectively channel precursor pools toward target pathways [110]. Deletion of competing pathways and flux redistribution further enhance effective precursor allocation. Although genome streamlining is discussed in Section 4.2.2, its metabolic consequence is particularly evident at the flux level. In S. tsukubaensis, deletion of transcriptionally active PKS clusters generated a cleaner metabolic background and increased FK506 production by 21.4%, reflecting improved precursor channeling toward the target pathway [104,111]. Likewise, in the Micro-HEP platform, multi-copy integration of heterologous BGCs via recombinase-mediated cassette exchange (RMCE) demonstrated a positive correlation between gene copy number and metabolite yield, effectively increasing pathway demand and redirecting intracellular precursors toward the introduced biosynthetic system [112]. Redox balancing and cofactor engineering have emerged as additional determinants of biosynthetic efficiency. Many PKS and NRPS systems rely heavily on NADPH-dependent reductive reactions. Functional studies of tailoring enzymes and trans-AT PKS pathways emphasize that adequate NADPH supply is essential for sustaining enzymatic turnover and preventing metabolic bottlenecks [113]. Reviews of Streptomyces metabolic engineering consistently highlight that optimization of pentose phosphate pathway activity and redox regeneration systems can significantly enhance secondary metabolite production capacity [114]. These findings underscore that redox homeostasis is not a passive parameter but an active engineering target. ATP supply and energy metabolism optimization also influence biosynthetic robustness. Comparative analyses of newly engineered chassis strains reveal that hosts with stronger primary metabolism and higher biomass accumulation capacity consistently outperform conventional strains in expressing complex polyketide clusters [25,115]. For instance, engineered Streptomyces sp. A4420 CH demonstrated superior heterologous production relative to commonly used hosts, partly attributed to improved metabolic capacity and growth performance [115]. Similarly, newly developed chassis species such as S. sungeiensis SD3 exhibited favorable growth characteristics and compatibility with CRISPR-based editing, further supporting efficient heterologous biosynthesis [25]. In summary, optimizing precursor and cofactor supply represents a metabolic layer in Streptomyces chassis engineering. Through amplification of precursor pathways, deletion of competing sinks, redox balancing, and energy optimization, researchers have significantly strengthened metabolic flux toward target NPs. These strategies complement genome streamlining and provide the biochemical foundation for regulatory reprogramming approaches discussed in the following section. Regulatory reprogramming for silent BGC activation While precursor and cofactor optimization strengthens metabolic flux, transcriptional silencing and regulatory incompatibility often remain the dominant bottlenecks limiting heterologous BGC expression. Regulatory reprogramming has therefore become a necessary strategy in Streptomyces chassis engineering to overcome transcriptional repression and host-donor regulatory mismatch [91,102]. Global regulators orchestrate secondary metabolism, stress response, and morphological differentiation in Streptomyces. Reprogramming these higher-level regulatory circuits can shift the transcriptional landscape toward a more permissive state for BGC expression. Yan et al. demonstrated that reprogramming naturally evolved regulatory switches provides an effective strategy for chassis development and enhanced metabolite production [102]. Similarly, Kang et al. emphasize that regulatory network rewiring is essential for improving compatibility between heterologous BGCs and host transcriptional machinery [116]. Sigma factors control promoter recognition and RNA polymerase recruitment, thereby shaping global transcriptional output. Modulating σ-factor activity provides a higher-level strategy for enhancing secondary metabolism [102]. A representative example is the engineering of the primary sigma factor hrdB in S. avermitilis. Zhang et al. reported that modification of hrdB increased transcription of the pathway-specific regulator AveR, resulting in over a 50% increase in avermectin B1a production [117]. σ-factor modulation operates at a broad regulatory level and represents a promising strategy for chassis-level transcriptional optimization. Beyond global control, activation of cluster-situated regulators (CSRs) provides a direct means to unlock silent gene clusters. Takao et al. identified and heterologously expressed an atypical response regulator (kiqA), leading to significant enhancement of kinanthraquinone production in S. lividans [118]. This study clearly demonstrates that restoring or strengthening pathway-specific regulatory elements can overcome native transcriptional silence. Direct cloning and heterologous expression approaches also reveal cryptic metabolites when regulatory constraints are relieved. Qian et al. discovered streptoketides by cloning and expressing a cryptic type II PKS cluster in S. coelicolor, thereby bypassing the repressive regulatory context of the original host [119]. Similarly, heterologous reconstruction of the di-AFN A1 BGC in model Streptomyces strains significantly enhanced production compared with the native producer, illustrating how regulatory compatibility influences output [120]. These examples collectively show that pathway-specific regulatory tuning through CSR overexpression or reassembly in optimized hosts remains a highly effective activation strategy. Promoter engineering also provides a standardized and modular approach for decoupling BGC expression from native repression. Guo et al. identified a strong constitutive promoter, stnYp, which exhibited higher activity than commonly used promoters (ermEp∗, kasOp∗) across multiple Streptomyces hosts [110]. Replacement of native promoters with stnYp activated silent clusters and significantly increased metabolite titers, demonstrating that transcriptional strength alone can determine BGC activation status. Promoter refactoring is frequently integrated into multi-level metabolic engineering workflows. For example, systematic promoter optimization contributed to substantial improvements in fidaxomicin production in an engineered S. albus chassis [109]. Building upon these regulatory interventions, recent chassis engineering efforts increasingly integrate multiple layers of transcriptional control. For example, activation of cyclic peptides such as dudomycins and related metabolites in genome-reduced S. albus Del14 relied on a transcriptionally permissive chassis background [121,122]. Furthermore, multi-copy BGC integration within optimized heterologous expression systems enhanced product yields in part through improved transcriptional output [112]. Enhancement of process robustness and industrial scalability While genetic optimization improves metabolic performance, successful industrial application ultimately depends on fermentation stability, morphological robustness, and scale-up compatibility. In recent years, Streptomyces chassis engineering has increasingly incorporated process-oriented strategies to ensure reproducible production under large-scale fermentation conditions. Streptomyces species exhibit complex filamentous growth, forming mycelial pellets in submerged fermentation [123]. Pellet morphology directly influences oxygen transfer, nutrient diffusion, broth viscosity, and ultimately product yield. Controlling pellet size and mycelial architecture has therefore emerged as a critical strategy for improving fermentation robustness [124,125]. Genome-streamlined or refactored strains often display altered growth kinetics and biomass accumulation profiles, which can enhance industrial performance. For example, in S. tsukubaensis L19, deletion of competitive PKS clusters followed by pathway refactoring not only increased FK506 production by 21.4%, but ultimately enabled titers of 830.3 mg/L in a 15 L fermenter, demonstrating improved scalability of the engineered chassis [104]. This case illustrates how chassis modification can indirectly optimize bioreactor fermentation behavior alongside metabolic flux. Industrial fermentation subjects strains to high substrate concentrations, oxidative stress, osmotic pressure, and product toxicity. Enhancing stress tolerance is therefore essential for stable large-scale production. Streptomyces species possess intrinsic robustness, including strong secretion systems and inherent resistance to antibiotics, making them promising alternatives to traditional hosts such as E. coli for industrial bioprocesses [92,126]. In particular, strains with innate alkaline tolerance have been exploited for extracellular enzyme production under industrial conditions, simplifying downstream processing and improving process robustness [127]. Beyond laboratory optimization, industrial host domestication involves iterative adaptation to defined media, stable genetic configurations, and scalable fermentation regimes [128]. Integration of synthetic biology tools with process engineering enables rational refinement of chassis strains. CRISPR/Cas-based genome engineering and omics-guided DBTL cycles have accelerated the development of strains with improved growth characteristics and production stability [10]. Dynamic regulatory systems further enhance scalability. For example, the Streptomyces multiplexed artificial control system (SMARTS) enables predictable and scalable production across species and has demonstrated robust performance in industrial fermenters up to 120 m3, supporting efficient production of baiweimycin and epirubicin [129]. Such multiplexed regulatory frameworks provide adaptive control over metabolic flux under industrial conditions. Despite substantial progress, achieving a universally robust Streptomyces chassis remains challenging due to host-dependent differences in morphology, stress tolerance, and metabolic behavior [99]. Construction of non-classic chassis guided by phylogenetic host compatibility While Section 4.2.1 focuses on improving genetic manipulability, efficient heterologous expression also depends on intrinsic compatibility between the host and the introduced BGC [99]. Despite advances in genome editing, expression outcomes still vary substantially across Streptomyces species [90], underscoring the importance of phylogenetic proximity and host-cluster compatibility as evolutionary and systems-level determinants [9,99]. Comparative studies have demonstrated that expression success is often enhanced when the heterologous host is phylogenetically close to the BGC donor [25]. Closely related hosts are more likely to share similar GC content, codon usage patterns, promoter recognition systems, precursor supply networks, redox balance, and cytochrome P450 dependent tailoring capacity [92]. These intrinsic compatibilities reduce regulatory mismatch and metabolic burden, thereby increasing the probability of functional pathway reconstruction. The polyketide-focused CH strain derived from Streptomyces sp. A4420 further illustrates host-cluster matching. By deleting nine endogenous PKS clusters, Klumbys et al. generated a metabolically streamlined strain that retained robust growth and sporulation while outperforming classical chassis strains in heterologous polyketide production [115]. Likewise, Chassis2.0 developed from S. aureofaciens J1-022 exhibited markedly improved oxytetracycline production and enabled activation of a previously silent pentangular T2PKS cluster, underscoring the value of selecting hosts with intrinsic biosynthetic competence aligned to the target compound class [115]. For NRPS and hybrid PKS/NRPS pathways, genome-reduced derivatives such as Streptomyces sp. A-14 [107], S. griseofuscus DEL2 [130], and S. sungeiensis SD3 [27] demonstrate that phylogenetic positioning combined with targeted genome engineering can create hosts capable of accommodating structurally diverse gene clusters. In particular, SD3 showed compatibility with both polyketide-terpenoid hybrids and complex NRPS-derived metabolites [25]. Terpenoid biosynthesis provides another clear example of compatibility-driven design. Engineering of S. albus J1074 and S. avermitilis SUKA22 with enhanced MEP pathway modules enabled efficient production of structurally complex terpenoids requiring extensive P450-mediated tailoring [131]. The inherent oxidative capacity and post-modification machinery of Streptomyces hosts proved critical for achieving scalable terpenoid production. Marine-derived Streptomyces chassis expand this concept into ecological compatibility. Platforms such as MGCEP 1.0, developed from S. atratus SCSIO ZH16, are specifically adapted for marine BGC expression [132]. In addition, the marine sponge-derived strain Streptomyces sp. HNS054 has been developed as a genetically tractable chassis exhibiting rapid growth, salt tolerance, and compatibility with standard engineering tools. Its genome encodes 21 predicted biosynthetic gene clusters, and engineered variants achieved 4.5-fold and 1.2-fold increases in aborycin and actinorhodin production, respectively, compared with S. coelicolor M1346 counterparts, highlighting its potential as a marine-adapted production platform [133]. Similarly, newly characterized marine species harbor numerous cryptic BGCs and possess specialized metabolic networks shaped by marine ecological pressures [134,135], suggesting that environmental origin may influence host suitability for marine NP expression. Collectively, these studies demonstrate that chassis performance is not determined solely by genetic tractability or metabolic cleanliness, but also by evolutionary proximity and intrinsic biosynthetic architecture. Rather than pursuing a single universal host, emerging evidence supports the development of specialized chassis libraries tailored to pathway class, ecological origin, and industrial objective. Integrating phylogenetic analysis with synthetic biology and genome engineering therefore represents a rational framework for improving predictability and efficiency in Streptomyces heterologous expression systems. Application-oriented chassis selection framework While Section 4.1 quantitatively summarized recent heterologous expression trends across Streptomyces hosts, the accumulated case studies also reveal a more fundamental principle: chassis performance is not universally optimized but application-dependent. Rather than asking which host performs “best” overall, a more relevant question is which host architecture aligns most effectively with a given engineering objective. This shift from comparative analysis to decision-oriented design defines the core rationale of the application-oriented chassis selection framework. For NP discovery and cryptic BGC activation, the primary requirement is not maximal yield but maximal detectability and regulatory responsiveness. Hosts used in discovery-oriented studies are typically characterized by reduced endogenous metabolite backgrounds and strong regulatory plasticity. Genome-reduced derivatives of S. albus, S. coelicolor, and S. lividans exemplify this design logic: by minimizing competing pathways and enhancing transcriptional permissiveness, these strains increase the probability of activating silent clusters and identifying low abundance products. In this context, screening sensitivity, regulatory reprogramming capacity, and chromatographic clarity are prioritized over metabolic flux intensity [130,136]. For functional characterization of BGCs, beyond maintaining a relatively clean background metabolite profile, the design rationale pivots toward prioritizing genetic stability and regulatory predictability. Functional studies require controlled expression environments where transcriptional outputs can be interpreted mechanistically. Well characterized laboratory strains with stable integration systems and defined regulatory backgrounds are therefore preferred. Here, the objective is precise reconstruction and pathway dissection rather than discovery throughput or industrial yield. Host selection is guided by reproducibility, regulatory transparency, and compatibility with genetic toolkits [25,120]. For high-titer production and scale-up, chassis selection is driven by physiological robustness and metabolic strength. Industrial or semi-industrial derivatives capable of sustaining high precursor flux, redox balance, and fermentation stability become advantageous. In this scenario, regulatory permissiveness is secondary to metabolic capacity and process compatibility. Host evaluation extends beyond genetic manipulability to include fermentation behavior, scalability, and resilience under production conditions [137,138]. Taken together, these three design scenarios illustrate that chassis selection operates along multiple orthogonal dimensions: metabolic cleanliness, regulatory controllability, and production robustness. The empirical cases summarized in Table 2, Table 3, Table 4 therefore serve not merely as examples of success but as evidence supporting a structured, application-driven selection logic. Importantly, this framework complements the strategies outlined in Section 4.2 by shifting the focus from how to engineer a chassis to when and why to strategically select one. Together, these approaches reframe chassis development as an application-oriented systems design problem rather than a host optimization task. This shift highlights the necessity for a unified, systematic strategy. To address this, the following section presents the 5M strategy as a comprehensive, fermentation-oriented framework designed for industrial-scale rational engineering of Streptomyces chassis and overproduction of NPs, thereby enabling iterative and forward-planning processes. Table 2Heterologous expression in Streptomyces for new NP discovery (2020-2025).Table 2Source DNAHeterologous hostBGC familyCompoundReferenceS. albus ssp. Chlorinus NRRL B-24108S. albus Del14 and S. lividans Del8NRPSDudomycins A-D[122]S. cacaoi CA-170360S. albus J1074, S. coelicolor M1152 and M1154NRPSPentaminomycins A-H[154]S. albus ssp. chlorinus NRRL B-24108S. albus Del14NRPSBonsecamin[121]Streptomyces sp. WAC01529S. coelicolor M1154/pAMX4NRPSGP1416 and GP6738[155]S.ambofaciens ATCC23877S. avermitilis SUKA17NRPSAmbocidin A and B[67]Streptomyces sp. SNJ102S. albus J1074NRPSJejumide[156]Streptomyces sp. DSS69S. lividans GX28NRPSWeddellamycin[157]Streptomyces sp. NRRL F-5123S. coelicolor M1146NRPSDrimentine B[158]Streptomyces sp. LV45129S. albus Del14NRPSIchizinones A-C[159]Streptomyces aurantiacus LU19075S. lividans TK24NRPSDepsibosamycins B-D[160]Actinomyces sp.K17/9S.coelicolor M512NRPSKasichelin A[161]Staphylococcus aureusS. coelicolor A3(2)PKSNaphpyrones A-H[162]Kutzneria sp. CA-103260S. albus J1074PKSEpemicin A and B[163]S. globisporus C-1027S. globisporus C-1027PKSAnthraquinone derivatives[164]Micromonospora endolithicaS. albus Del14PKSLoseolamycin A1-A2, Loseolamycin 3-6[165]S. monomycini NRRL B-24309S. lividans TK24PKSGrianquinone A-C[166]Saccharothrix espanaensisS. lividans ΔYA6PKSPentangumycin, SEK90[167]S. neyagawaensis IFO13477S. avermitilis SUKA32PKSJBIR-157[168]Soil metagenomic libraryS. venezuelae YN01/SARPPKSTetracenomycin Y[169]S. olivaceus Tü2353, S. venezuelae ATCC 15439, S. antibioticus ATCC 11891, S. griseus subsp. griseus ATCC 13273, Streptomyces sp. KCTC 0041BP, S. griseoflavus Gö3592S. coelicolor M1146PKS8-O-d-olivosyl-tetracenomycin C, 8-O-d-digitoxosyl-tetracenomycin C, 8-O-d-mycarosyl-tetracenomycin C, 8-O-d-allosyl-tetracenomycin C, 8-O-d-fucosyl-tetracenomycin C[80]Soil metagenomeS. coelicolor M1146PKSCoelulatin A, Coelulatin B, DMAC[170]S. hygroscopicusS. avermitilis SUKA34:rapHPKSRapamycin derivative 1-4[171]BACS. coelicolor M1154PKSAnsamycins[172]S. formicae KY5S. coelicolor M1146PKSFormicamycins[173]Streptomyces sp. IB201691-2AS. albus J1074PKSBaikalomycins A–C[174]S. parvus 1268S. lividans TK64PKSCarpatamides N–R[175]S. globisporus SCSIO LCY12S. coelicolor M1152PKSGlobismycin A and B, Bhimamycin J[176]Streptomyces sp. RI-77S. albusPKSAvenalumic acid[177]Streptomyces sp. KIB-H91S. coelicolor M1154PKSSarubicin A and B, Quinazolinone 3-5[178]Soil metagenomic libraryS. albus J1074PKSAngucystemycin A, Angucystemycin B, Emycin H[179]S. strain KIB-H91S. coelicolor M1154PKSSarubicins A and B[178]Lysobacter sp. DSM 3655Streptomyces sp. S001PKSLysohexaenetides A and B[180]Streptomyces argillaceusS. albusPKSMetathramycin[181]Saccharopolyspora erythraea NRRL 23338S. albus B4PKS6-Methylsalicylic acid; 6-Ethylsalicylic acid[182]Streptomyces sp. RK18-A0406 genomic DNAStreptomyces sp. RK18-A0406PKSElasnin A1–A3, Elasnin B1–B3, Elasnin C1–C3, Proelasnin A1, Proelasnin B1, Proelasnin C1[183]Streptomyces sp. AM4900S. avermitilis SUKA54PKS12-ketomethymycin N-oxide[65]Streptomyces sp. B59S. albus J1074PKSShuangdaolides A–D and Dumulmycin[184]S. eurocidicus CGMCC 4.1086S. albus J1074PKSNaphthocyclinones 1–3[185]Dactylosporangium aurantiacumS. albus J1074PKSFidaxomicin[79]S. chrestomyceticus BCC 24770S. coelicolorPKSAlbofungins A and B[186]Streptomyces sp. HDN155000S. albus J1074PKSWS009 Z, Angumycinone T and Angumycinone X[164]S. reveromyceticus SN-593-44S.lividans TK23PKSKinanthraquinone C and D[187]Streptomyces sp. LS-1S. coelicolor A3(2)-2023PKSGriseorhodin H[112]Streptomyces sp. Tü6314S. coelicolor M1152 and M1154PKSStreptoketides A and B[119]S. indonesiensisS. albus J1074PKSAcidonemycins A–C[188]S. atratus Gö66S. albus J1074TerpeneAtralabdans A–C[189]S. levis MCCC1A01616S. coelicolor M1146TerpeneLevinoids A–D[190]S. melanosporofaciensS. albus J1074TerpeneSmelanic acid[191]S. eurocidicus CGMCC 4.1086S. albus J1074 MTerpeneSesquiterpene[192]S. mirabilis Lu17588S. albus Del14Hybrid-PKS/NRPSMiramides A–D[193]S. spiroverticillatus JC-8444S. avermitilis SUKA17Hybrid-PKS/NRPSVerticilactams B and C[66]Amycolatopsis cihanbeyliensis DSM 45679S. lividans SBT18Hybrid-PKS/NRPSEfrotomycin A1–A4[194]Kitasatospora sp. S023Streptomyces sp. S001Hybrid-PKS/NRPSClifednamides D and E, Clifednamides F–J[195]Streptomyces sp. CNT360S. coelicolor M1152Hybrid-PKS/NRPSSulfenicin[196]S. fimbriatus ATCC 15051S. albus 1597RiPPSeptacidin 538, Septacidin 552[197]Streptomyces sp. SCSIO 11878S. lividans SBT18, S. coelicolor M1154RiPPBerninamycins A and B[198]S. purpureus, S. lavendulae, S. xanthophaeus, S. cinnamoneus, Streptomyces sp. NRRL S-1868, Saccharopolyspora antimicrobicaS. coelicolor, S. albus J1074RiPP1-(8-guaninyl)-cWW (guanitrypmycin C3-1), Guatrypmethine C, Aspergilazine A, Naseseazine A, Tetratryptomycins[199]Streptomyces sp. SCSIO 11878S. albus J1074RiPPBerninamycins J and K[198]S. thermolilacinus SPC6S. albus J1074RiPPDmxorosin[200]Kutzneria albida DSM 43870S. albus Del14OtherHuimycin[201]eDNAS. albus J1074 and S. coelicolor M1146OtherIsoquinolinequinones[202]Streptomyces sp. 4-L-3S. albus J1074OtherLansai G[203]Streptomyces albus subsp. chlorinus NRRL B-24108S. albus Del14OtherBenzanthric acid[82]Micromonospora sp. SCSIO 07395S. albus Del14OtherMicroechmycin A–E[204] Heterologous expression in Streptomyces for new NP discovery (2020-2025). Table 3Heterologous expression in Streptomyces for functional characterization of BGCs (2020–2025).Table 3Source DNAHeterologous hostBGC familyCompoundReferenceStreptomyces sp. CA-278952S. albus J1074 and S. coelicolor M1146NRPSGlobomycin[205]Streptomyces sp. ATCC 700974S. coelicolor M1146, S. lividans TK24, S. albus J1074NRPSAlbomycin[206]S. filamentosus NRRL 15998S. albus Del14NRPSDaptomycin[83]S. fragilisS. albus J1074NRPSAzaserine[207]S. atratus SCSIO ZH16S. coelicolor M1152NRPSIlamycins[208]S. durhamensis NRRL-B3309S. coelicolor M512NRPSCystargolide A and B[209]Tistrella mobilisS. coelicolor M1152NRPSDidemnin B, Nordidemnin B[210]Actinomadura sp. RB29S. albus J1074PKSMaduralactomycin A[211]S. strain KIB-H91S. coelicolor M1154PKSSarubicins A and B[178]Soil metagenomeS. coelicolor M1146PKSCoelulatin A, Coelulatin B, DMAC[170]Soil metagenomic libraryS. venezuelae, S. coelicolor M1146PKSTetracenomycin X[169]Streptomyces sp. RI-77S. albusPKS3-Aminoavenalumic acid, N-acetyl-3-aminoavenalumic acid[177]Streptomyces sp. IB201691-2AS. albus J1074PKSBaikalomycins A-C[174]S. globisporus SCSIO LCY12S. coelicolor M1152PKSMedermycin, G-15F, DMAC, Aloesaponarin II, 1,4,7-trihydroxy-9-methyl-anthraquinone, 1-hydroxy-6-methoxy-8-methyl-anthraquinone[176]Soil metagenomic libraryS. albus J1074PKSRubiginone B2, Emycin C, Rubiginone B1, Ochromycinone, Emycin A[179]S. albus subsp. chlorinus NRRL B-24S. explomaris 4N24PKSNybomycin[212]Marinispora CNQ-140S. lividansPKSMarinomycin[213]Amycolatopsis sp. DEM30355S. coelicolor M1152PKSTatiomicin[214]S. arenae DSM 40737S. albus J1074PKSα-Naphthocyclinone acid[215]BACS. coelicolor M1154PKSAnsamycins[172]Saccharopolyspora erythraea NRRL 23338S. albus B4PKS6-Methylsalicylic acid; 6-Ethylsalicylic acid[182]Streptomyces sp. B59S. albus J1074PKSShuangdaolides A–D and Dumulmycin[184]S. roseosporus NRRL 15998Streptomyces sp. A4420PKSAuroramycin[115]S. eurocidicus CGMCC 4.1086S. albus J1074PKSNaphthocyclinones 1–3[185]Streptomyces sp. CS-7S. albus J1074PKSMayamycin, Mayamycin B[216]Amycolatopsis sulphurea CHDS. albus Del14PKSChelocardin[217]S. olivaceus Tü2353S. coelicolor A3(2)PKS8-Demethyl-tetracenomycin C[218]S. neyagawaensis IFO13477S. avermitilis SUKA32PKSent-Gephyromycin[168]Frankia alni ACN14aS. albus 9B-A9PKSFralnimycin[219]BACS. avermitilis SUKA32PKSConcanamycin, ent-Gephyromycin, JBIR-157[220]Amycolatopsis sulphurea NRRL 2822S. albus Del14PKSChelocardin[83]S. agglomeratus 5-2-6S. coelicolor M1152PKS(2S,3Z,5E,7R,8R)-1,1-Dichloro-7-methyldeca-3,5-diene-2,7,8-triol, (2S,3Z,5E,7S,8R)-1,1-Dichloro-7-methyldeca-3,5-diene-2,7,8-triol[221]Streptomyces sp. S1502S. lividans SBT5PKSWS-5995 B–E[222]S. olivaceus Tü2353S. coelicolor M1146PKSTetracenomycin derivatives[80]S. monomycini NRRL B-24309S. lividans TK24PKSKS-619-1[166]S. nitrosporeus ATCC 12769S. lividans TK24PKSAnthrapyrone A–C[166]S. lividans 1326S. lividans 1326, S. lividans TK24PKSBisenarsan, 2,4,6-TMNA[223]Photorhabdus luminescens TT01S. albus J1074, S. lividans TK23PKSFlavokermesic acid, Sek4, Sek4b, dehydro-Sek4, dehydro-Sek4b[224]Streptomyces sp. KIB-H91S. coelicolor M1154PKSSarubicin A and B, Quinazolinone 3-5[178]Kutzneria sp. CA-103260S. albus J1074PKSEpemicin A and B[163]S. roseochromogenes NRRL 3504S. albus Del14, S. lividans ΔYA9PKSLimocrocin[225]S. peucetiusS. venezuelaePKSEpidoxorubicin[129]Streptomyces sp. QL37S. coelicolor M1152PKSLugdunomycin/Angucyclines[226]Amycolatopsis saalfeldensisS. coelicolor M1146, S. lividans TK24, S. albus J1074PKSAvaroferrin[227]Rhodobacter sphaeroidesS. coelicolor M145PKSTriacetic acid lactone[228]S. tasikensis P46S. sungeiensis SD3Hybrid-PKS/TerpeneFuraquinocin M[25]Streptomyces sp. DSM26212S. coelicolor M1146Hybrid-PKS/NRPSPseudouridimycin[229]S. mirabilis P8-A2S. albus J1074, S. coelicolor M1146Hybrid-PKS/NRPSAzodyrecins[230]Amycolatopsis cihanbeyliensis DSM 45679S. lividans SBT18Hybrid-PKS/NRPSCihanmycin C and D[231]S. spiroverticillatus JC-8444S. avermitilis SUKA17Hybrid-PKS/NRPSVerticilactams B and C[66]gDNAS. albus DSM 40313, S. lividans TK24, S. coelicolor M1154Hybrid-PKS/NRPSIkarugamycin[232]Streptomyces sp. CNT360S. coelicolor M1152Hybrid-PKS/NRPSSulfenicin[196]Streptomyces sp. SCSIO 68065S. atratus ZH16NSEPKHybrid-PKS/NRPSPepticinnamin Q–V[233]Streptomyces sp. CNT360S. coelicolor M1152Hybrid-PKS/NRPSSulfenicin[178]Streptomyces sp. PKU-MA01144S. lividans SBT5Hybrid-PKS/NRPSPepticinnamin G–I[234]S. conglobatusS. albus J1074Hybrid-PKS/NRPSUnantimycins B–E[235]Kitasatospora sp. S023Streptomyces sp. S001Hybrid-PKS/NRPSClifednamides A and B[195]Amycolatopsis tolypomycina NRRL B-24205S. albus J1074, S. lividans SBT18MeroterpenoidAtolypene A[236]Helotiales sp. BL73S. coelicolor M1154, S. albus Del14, S. venezuelae T1-4D, S. coelicolor M1154,TerpeneLinalool, Linalyl oxide[237]S. nojiriensis NRRL B-16930S. lividans TK24Terpene5-DMAIAN[166]S. thermolilacinus SPC6S. albus J1074RiPPDmxorosin[200]S. pseudovenezuelae NA07851S. albus J1074RiPPPseudovenmycin[238]S. bikiniensis ISP 5582S. lividans TK24RiPPCypemycin[166]S. yunnanensisS. coelicolor M1154, S. lividans GX28RiPPYunnanaridin A–C[239]S. cinnamoneus DSM 40646S. albus J1074RiPPGuatrypmethine C[240]Streptomyces sp. PKU-MA01240S. coelicolor A3(2), S, lividans K4-114RiPPStlassin[241]S. cacaoi CA-170360S. albus J1074RiPPCacaoidin[242]Kitasatospora purpeofusca HV058S. lividans TK24OtherHazimycin[243]Streptomyces albus subsp. chlorinus NRRL B-24108S. albus Del14OtherNybomycin[82]Streptomyces sp. NRRL F-5635S. lividans TK24OtherAerugine, Watasemycin B[166]S. aureus LU18118S. albus Del14OtherLipothrenin 1–14[244]S. leeuwenhoekii NRRL B-24963S. albus J1074OtherStreptoazine A–C[245]S. albus Del14Streptomyces LV1−652OtherMansouramycin A and D[246]S. albus subsp. pathocidicus CGMCC4.1633S. albus J1074Other8-Azaguanine[247]Streptomyces sp. NRRL S-515S. lividans 66Otherl-Phosphonoalanine (PnAla), Phosphonoalamides A–D[248]Micromonospora sp. SCSIO 07395S. albus Del14, S. albus J1074OtherMicroechmycin A and F[204]Streptomyces sp. 4-L-3S. albus J1074OtherLansai A and B[203]S. albus subsp. chlorinus NRRL B-24108S. albus J1074OtherAlbucidin[249]Kitasatospora setae NBRC 14216TStreptomyces sp. PRh3-r55KOtherJBIR-133, JBIR-134, Kitasetaline, Novkitasetaline[250]S. albus subsp. chlorinus NRRL B-24108S. albus Del14OtherAlbucidin[251] Heterologous expression in Streptomyces for functional characterization of BGCs (2020–2025). Table 4Heterologous expression in Streptomyces for production yield improvement (2020–2025).Table 4Source DNAHeterologous hostBGC familyCompoundReferencePCR-amplified linear DNAS. albus J1074 and S. lividans TK24NRPSIndigoidine[152]Streptomyces sp. WAC01529S. coelicolor M1154/pAMX4NRPSCorbomycin[155]Actinoplanes utahensisS. coelicolorNRPSDaptomycin[184]Streptomyces sp. RK18-A0406 genomic DNAStreptomyces sp. RK18-A0406NRPSAntimycin derivatives[183]S. acidisabies ATCC 49003S. venezuelae ISP5230, S. albus J1074 and S. coelicolor M1154NRPSThaxtomin A[84]S. roseosporus NRRL 11379S. coelicolor A3(2)NRPSDaptomycin[252]S. scabies CGMCC 4.1765S. albus J1074NRPSThaxtomin A[253]S. staurosporeus AM-2282S. avermitilis ATCC 31267, S. lividans TK24 and S. albus J1074NRPSStaurosporine[85]Actinoplanes deccanensisS. albus D7-VHbPKSFidaxomicin[109]S. albus subsp. chlorinus NRRL B-24108S. albus 4N24, NYB-6B, NYB-11PKSNybomycin[254]S. albus subsp. chlorinus NRRL B-24S. explomaris NYB-1, NYB-2, NYB-3A, NYB-3B, NYB-3C, NYB-4PKSNybomycin[212]Soil metagenomic libraryS. venezuelae, S. coelicolor M1146/YN01/SARPPKSTetracenomycin X[169]Rhodobacter sphaeroidesS. coelicolor M145PKSTriacetic acid lactone[228]Saccharopolyspora erythraeaS. albus B4PKS(R)-(-)-mellein[255]Saccharopolyspora spinosaS. albus J1074PKSSpinosyns[81]cloning of large DNA fragmentsS. fradiae ATCC 19609, S. coelicolor M1146PKSTylosin[256]Saccharopolyspora spinosaS. coelicolor M1146PKSSpinosad[138]Saccharopolyspora spinosaSt. fradiae J1−021PKSSpinosad[137]S. nobilis JCM4274S. lividans TK23PKSDesertomycin[257]Artificial gene clusterS. coelicolor CH999, S. lividans K4‐114, S. albus J1074PKSSalinomycin[258]S. cyanogenus S135S. lividans RedStrep 1.3, S. lividans TK24PKSUWM6, Rabelomycin, Mithramycin A[259]Saccharopolyspora spinosaS. albus B4PKSSpinosad[260]S. rubrisoli Inha501S. lividansPKSInha-Neotetrafibricin[261]Marinispora CNQ-140S. lividansPKSMarinomycin[213]Streptomyces sp. AD-3-6S. albus NYB-11PKSNybomycin[254]S. antibioticusS. coelicolor M1152PKSOviedomycin[144]Microbispora rosea subsp. hibaria TP-A0121S. coelicolor M1154PKSHibarimicin B[262]Amycolatopsis sulphurea CHDS. albus Del14PKSChelocardin[217]Streptomyces sp. LS-1S. coelicolor A3(2)-2023PKSGriseorhodin H[112]PCR-amplified linear DNAS. albus J1074 and S. avermitilis SUKA22Terpene(-)-epi-α-bisabolol, ent-(13Z)-isocupressic acid, ent-(13E)-isocupressic acid and ent-atiserenoic acid[131]Streptomyces sp. Tü 6239S. albus KO5Hybrid-PKS/NRPSIkarugamycin[263]Streptomyces sp. SIPI 506S. albus J1074Hybrid-PKS/NRPSStaurosporine[85]Amycolatopsis cihanbeyliensis DSM 45679S. lividans SBT18Hybrid-PKS/NRPSEfrotomycin A1-A4[194]Streptomyces sp. HNS054S. coelicolor M1346RiPPAborycin[151]Planobispora roseaS. coelicolor M1146RiPPGE2270A[264]Oryza sativaS. albus UO-FLAV-004OtherSakuranetin, Acacetin and Genkwanin[265]S. hygroscopicus var. jinggangensis TL01S. albus J1074OtherValidamycin A[266]Petroselinum crispumS. albus UO-FLAV-004 -NAROtherAromadendrin and Taxifolin[267]S. ghanaensis ATCC14672S. albus J1074OtherMoenomycin A[268] Heterologous expression in Streptomyces for production yield improvement (2020–2025). 5M strategy-oriented Streptomyces NPs overproduction framework In Streptomyces synthetic biology, the 5M strategy, encompassing Mechanism, Model, Manipulate, Measure, and Manufacture (as illustrated in Fig. 3), provides a systematic framework for elucidating and optimizing secondary metabolite biosynthesis [139,140]. The 5 M strategy offers a workflow inspired by Design-Build-Test-Learn (DBTL) cycles, extended with a manufacturing focus to bridge lab-scale discoveries to industrial applications. For instance, the Mechanism leverages multi-omics datasets to uncover the underlying principles of intracellular metabolism, thereby identifying targets for deciphering NP biosynthesis. Model integrates computational modeling, predictive simulation, and systems-level analysis to quantitatively associate metabolic intermediates, energy fluxes, and regulatory circuits with product formation, enabling in silico design optimization. At the Manipulate stage, precise genetic and regulatory modifications are programmed to rewire metabolic pathways and dynamically regulate metabolic switches, thereby enhancing productivity and robustness. Measure then implements rigorous and quantitative assessment of engineered strains, including flux mapping, metabolite profiling, and phenotypic characterization, to ensure iterative optimization. Finally, Manufacture advances pilot-scale validation toward industrial-scale production, achieving scalable production. Notably, based on a thorough understanding of strain metabolic mechanisms and strain-bioreactor adaptation mechanisms, the 5 M strategy is oriented towards industrial applications, facilitating continuous iteration and optimization of chassis design and regulation to meet the demands of scalable production, enhanced yield efficiency, and robust performance in biomanufacturing processes. 5M Strategy principle. Schematic of the 5M Strategy Principle integrating strain development (left panel) and bioprocess development (right panel) through five core elements: Mechanism, Model, Manipulate, Measure, and Manufacture. The left panel (Strain development) is governed by Mechanism (Metabolic Switching and Regulatory Principles of Strains) and Manipulate (precise reconstruction and testing of metabolic and regulatory networks). It shows the integrated workflow of Tools–Element–Module Integrated Design together with Testing, Decoupling and Modeling that ultimately yields high-yield strains oriented toward manufacturing goals; The right panel (Bioprocess development) is governed by Mechanism (Synergistic Principles of Strain-Process-Equipment) and Manufacture (intelligent optimization and demonstration validation of the integrated manufacturing process). It illustrates the cross-scale workflow of Multi-Scale Coupling Modeling and Fermentation Process Cross-Scale Characterization leading to Scale-Up and Industrial Production. Model and Measure exist in both the left and right panels. With the goal of scale-up production, they drive continuous iteration, optimization, and upgrading, forming a closed-loop synergistic system. Our study establishes a paradigm for applying the 5M strategy in Streptomyces synthetic biology. Through integrative metabolomic and transcriptomic profiling, we revealed the physiological role of intracellular triacylglycerols (TAGs) in polyketide biosynthesis, deciphering the underlying mechanism that governs the metabolic switch from the primary to the secondary phase [86]. By characterizing the fatty acyl-CoA synthetase gene (sco6196) and developing the dynamic degradation of TAGs (ddTAG) strategy, we constructed a robust chassis model and manipulated it to enable quantitative assessment of the yields of actinorhodin, jadomycin B, oxytetracycline, and avermectin B1a. Remarkably, in the Manufacture phase, this approach demonstrated excellent scalability-yielding a 50% increase in avermectin B1a production, reaching 9.31 g/L in a 180 m3 industrial fermentation-thereby underscoring the great potential of chassis engineering guided by the 5M framework. Furthermore, a universal and plug-in regulatory platform, SMARTS (Streptomyces Multiplexed Artificial Regulation System), exemplifies the 5M framework in Streptomyces, as demonstrated in our recent study [129]. By elucidating the conserved DNA-binding domains of quorum-sensing (QS) receptors across different Streptomyces species, the mechanism underlying cross-species signal recognition was uncovered, providing the model for designing the universal QS-triggered promoter, Ptrig. Building upon this foundation, a bistable circuit and multiplex module integrating ECF σ factors and CRISPRi control were constructed to orchestratly manipulate multi-target gene expression. Functional validation (measure) confirmed orthogonal, predictable, and robust regulation without perturbing native networks. In the manufacture phase, SMARTS-guided strains demonstrated industrial scalability: S. avermitilis produced 8.4 g/L baiweimectin in 120 m3 fermenters-highlighting SMARTS as a versatile and robust platform for precision regulation and large-scale biosynthesis. Following the demonstration of the 5M framework in Streptomyces, its versatility and scalability in industrial biomanufacturing were expanded to the microbial production of porphyrins and their metal derivatives, integrating in vivo metabolic engineering and in vitro enzymatic catalysis [141]. Using Rhodobacter sphaeroides as a representative model, we have elucidated the mechanism underlying heme metabolic regulation and manipulated key nodes, including fnrL deletion and hemN modulation, to enhance the accumulation of the precursor coproprophyrin III (CPIII). Fine-tuning of the PrrAB two-component system, coupled with optimized fed-batch fermentation, enabled CPIII production up to 16.5 g L−1. Functional measure was achieved through high-throughput CRISPR-dCas12a and HrtR-Cas12a platforms, providing precise control over metabolic flux and enzymatic activity. Furthermore, in vitro conversion using ferrochelatase (HemH) and an engineered decarboxylase (HemQ28-M) achieved up to 98% efficiency and >20 g L−1 of metal-porphyrin derivatives. At the manufacture level, pilot-scale (200 L) fermentations yielded 19.6 g L−1 CPIII with >95% purity. Collectively, these studies exemplify how the 5M-guided strategy bridges fundamental understanding and scalable biomanufacturing, providing a robust and generalizable platform for accelerating the discovery, optimization, and industrial-scale production of high-value NPs. Future perspectives: toward intelligent and modular Streptomyces chassis design Despite the substantial progress in Streptomyces chassis engineering, several critical challenges remain that limit its full industrial and translational potential. The large genome size and high GC content complicate genetic manipulation compared with simpler hosts such as E. coli or yeast. In addition, the complex life cycle of Streptomyces and the multilayered regulation of its BGCs create barriers to precise metabolic control and scalable optimization. These limitations underscore the need for next-generation engineering strategies that integrate computational prediction, multi-target genome editing, and systems-level design (Fig. 4). Future perspectives for Streptomyces chassis development. (A) Tailored Streptomyces hosts for the heterologous expression of diverse natural product biosynthetic pathways. (B) Application of computational tools to advance Streptomyces chassis design and natural product biosynthesis. (C) Modular co-culture strategies to enhance functional optimization and division of labor in Streptomyces-based production systems. (D) Integration of enzymatic catalysis with engineered Streptomyces chassis for efficient and scalable industrial bioproduction. Customized heterologous expression host strategies in Streptomyces are tailored to the distinct biosynthetic requirements of polyketides, NRPs, terpenes, and other NPs. Although recent efforts have led to the development of Streptomyces chassis specifically tailored for PKSs [115] and terpenoids [131], these successes demonstrate the potential for constructing customized hosts for different classes of natural products. Despite substantial progress, major bottlenecks persist in Streptomyces research and application. These include difficulties in constructing high-yield industrial strains, the intricacy of regulatory networks involving multiple genetic targets, the limited flexibility of current chassis strains, and insufficient precision in metabolic network engineering. Addressing these issues requires continued advances in strain development and systems-level optimization. In particular, there is a pressing need for more powerful and versatile genome engineering technologies that can efficiently manipulate complex Streptomyces genomes and enable rational, multi-target metabolic redesign. Recently, Dr. Chengzhang Fu's team developed ACTIMOT (Advanced Cas9-mediated In vivo Mobilization and Multiplication of BGCs) [142], a CRISPR-Cas9-based strategy designed to unlock the vast chemical diversity encoded in bacterial genomes. ACTIMOT employs Cas9-induced double-strand breaks and homologous recombination to excise and amplify entire BGCs directly on the chromosome. The amplified clusters are then integrated into self-replicating plasmids in vivo, enabling efficient cross-host transfer and heterologous expression. By completing BGC amplification and mobilization within the host, ACTIMOT circumvents the limitations of conventional in vitro cloning that involve manipulating large genomic fragments. This approach markedly enhances the efficiency, fidelity, and scalability of BGC mining, providing a versatile platform for activating silent pathways and expanding the biosynthetic potential of Streptomyces chassis strains. Integration of computational tools, ML and AI to improve Streptomyces chassis design and accelerate NP biosynthesis. The integration of computational tools like genome-scale metabolic modeling (GEM), ML and AI will also play a crucial role in predicting metabolic pathways, optimizing precursor supply, and identifying bottlenecks in NP production. For instance, the development of a GEM for S. albus J1074, named Salb-GEM, has enabled accurate predictions of growth and glucose consumption rates, which align well with experimental data [143]. Boncheol Gu et al. [144] also utilized GEM to predict metabolic flux distributions associated with the precursors of secondary metabolites under specific conditions. This approach led to the successful production of the valuable polyketide oviedomycin through a combination of BGC cloning, promoter refactoring, and targeted manipulation of host metabolism, supported by genome-scale metabolic simulations. These works further underscore the potential of integrating computational models with combined engineering strategies to enhance NP biosynthesis and optimize Streptomyces chassis for secondary metabolite production. Machine learning is also being used to predict cryptic BGC activation and optimize heterologous expression conditions. Recent work by Yongjae Lee et al. [145] applying independent component analysis (ICA) to the transcriptome of S. coelicolor provides valuable insights into the regulation of secondary metabolism, offering new opportunities for enhancing NP production. Modular co-culture strategy for Streptomyces chassis optimization. While Streptomyces produces a wide range of NPs, no single species is efficient at synthesizing all types. In recent years, the emergence of the "module co-culture" strategy has introduced new opportunities for the application of Streptomyces as a chassis host. This approach involves co-culturing multiple microbial modules that function collaboratively to accomplish the synthesis of complex metabolic pathways. For example, Tan Liu et al. [146] successfully co-cultured Streptomyces sp. 2-85 and Cladosporium sp. 3-22, leading to the production of 19 unique compounds that were exclusively generated through co-culture. Among these, borrelidin exhibited significant antifungal activity against Saprolegnia parasitica, highlighting its potential as a biocontrol agent. This strategy not only alleviates the metabolic burden on individual chassis strains during pathway optimization but also enables rapid reconstruction of metabolic pathways by combining different modular strains. The continued advancement of module co-culture is expected to offer innovative solutions for optimizing Streptomyces-based chassis and achieving efficient NP production. Integration of in vivo metabolic flux reprogramming with in vitro enzymatic catalysis. The integration of in vivo metabolic flux reprogramming with in vitro enzymatic catalysis has emerged as a powerful strategy to enhance the biosynthesis of high-value natural products. In recent years, Streptomyces chassis have been extensively engineered to construct high-yield industrial strains, enabling the biosynthesis of key intermediates through pathway reconstruction and multi-source metabolic integration. These intermediates can then be efficiently converted into target products via in vitro enzymatic or organic catalysis. Rasor et al. [147] have established an integrated in vivo-in vitro metabolic engineering framework that combines cell-free systems with genetically rewired host strains. In this approach, cell extracts from S. cerevisiae strains modulated by multiplexed CRISPR-dCas9 and other metabolic engineering techniques were used to enhance the conversion of glucose to 2,3-butanediol, achieving volumetric productivities exceeding 0.9 g L−1 h−1. This strategy was further extended to improve in vitro biosynthesis of itaconic acid and glycerol, highlighting the broad applicability of coupling cellular flux reprogramming with cell-free catalysis for synthetic biology prototyping and sustainable biomanufacturing. Conclusion Streptomyces species are effective efficient microbial chassis for NP discovery and biosynthesis, owing to their exceptional secondary metabolic diversity and genetic adaptability. Their genomes harbor abundant PKS, NRPS, terpene, RiPP, and hybrid biosynthetic gene clusters, supported by diverse tailoring enzymes, intrinsic self-resistance mechanisms, and compatibility with complex enzymatic cascades, making them highly suitable for heterologous expression and combinatorial biosynthesis. The integration of AI-enhanced genomic mining tools with advanced genome engineering platforms such as CRISPR/Cas systems has further transformed Streptomyces from traditional antibiotic producers into rationally engineered chassis capable of systematic pathway reconstruction. Guided by application-driven selection principles and system-level engineering framework, chassis development is increasingly conceptualized as an integrated systems design process bridging molecular engineering and industrial biomanufacturing. However, substantial challenges persist, including precise multi-target regulation of complex pathways, mitigation of metabolic interference, maintenance of robustness during large-scale fermentation, and exploration of non-canonical chassis alternatives, issues that will define the next stage of Streptomyces chassis evolution. CRediT authorship contribution statement Simin Chen: Writing – review & editing, Writing – original draft, Investigation, Data curation, Conceptualization. Siqi Ling: Writing – review & editing, Investigation. Jinpin Li: Writing – review & editing. Zhiyan Liu: Investigation, Data curation. Lixin Zhang: Writing – review & editing, Supervision, Funding acquisition. Jingyu Zhang: Writing – review & editing, Supervision, Project administration, Funding acquisition. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Lixin Zhang is the Founding Editor for Synthetic and Systems Biotechnology and was not involved in the editorial review or the decision to publish this article. Acknowledgements This work was supported by the National Key Research and Development Program of China (2020YFA0907200), the National Natural Science Foundation of China (32571667), Natural Science Foundation of Shanghai (24ZR1417000), Shanghai Excellent Young Academic Leader Program of Eastern Talent Plan (QNKJ2025047), the Funds for International Cooperation and Exchange of the National Natural Science Foundation of China (W2412094), Key R & D Program of Shandong Province, China grant 485 (2022SFGC0104), Open Project Funding of the State Key Laboratory of Bioreactor Engineering, the 111 Project (B18022), and the Fundamental Research Funds for the Central Universities. Footnotes Peer review under the responsibility of Editorial Board of Synthetic and Systems Biotechnology. References